<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35501">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644395</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-2012-417</org_study_id>
    <nct_id>NCT02644395</nct_id>
  </id_info>
  <brief_title>Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus</brief_title>
  <acronym>TT</acronym>
  <official_title>Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Calcineurin inhibitors (CNIs) are the most commonly used immunosuppressive drugs
      to prevent rejection after kidney transplantation. However, the efficacy of preventing
      rejection comes at the cost of important side-effects. Among the most common side-effects is
      hypertension. Hypertension after kidney transplantation is clinically relevant, because it
      increases the risk of cardiovascular disease and is associated with increased graft loss and
      recipient mortality. The mechanism of CNI-induced hypertension is incompletely understood
      and, therefore, the treatment is currently empiric. These and other investigators recently
      showed that CNIs cause salt-sensitive hypertension by activating a sodium transporter in the
      kidney, namely the thiazide-sensitive sodium chloride cotransporter.

      Hypothesis: The investigators hypothesize that thiazide diuretics are non-inferior to
      calcium channel blockers (CCBs) (currently usually the treatment of choice) for the
      treatment of CNI-induced hypertension.

      Objective: To compare the blood pressure response to thiazide diuretics and CCBs in patients
      with CNI-induced hypertension.

      Study design: Single-center, randomized cross-over trial.

      Study population: Kidney transplant recipients with a good functioning allograft (eGFR &gt; 30
      ml/min) who are hypertensive (daytime systolic blood pressure &gt; 140 mm Hg) and who do not
      have proteinuria (&lt; 1 g/day).

      Intervention: Patients will be randomized to receive chlorthalidone (12.5 mg once daily, if
      needed titrated to 25 mg once daily) or amlodipine (5 mg once daily, if needed titrated to
      10 mg once daily).

      Main study parameters/endpoints: 24-hour blood pressure recording.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness: Both drugs have long been registered for the treatment of hypertension. The
      side-effect profile of both drugs is considered to be equal. The burden of the study for the
      patients are blood pressure measurements using 30-minute automated blood pressure
      measurement and 24-hour ambulatory blood pressure measurement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average daytime SBP</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Hypertension</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Current treatment of choice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorthalidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testing new indication for approved drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone</intervention_name>
    <description>Drug</description>
    <arm_group_label>Chlorthalidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Drug</description>
    <arm_group_label>Amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kidney transplant recipients using tacrolimus

          -  Average daytime SBP &gt; 140 mm Hg (ABPM)

          -  eGFR &gt; 30 ml/min (MDRD)

        Exclusion Criteria:

          -  Use of glucocorticoids, co-trimoxazole, diuretics

          -  Pregnancy

          -  Serum sodium &lt; 136, serum potassium &lt; 3.5

          -  Proteinuria &gt; 1 g/day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ewout J Hoorn, MD, PhD</last_name>
    <phone>+31107040704</phone>
    <email>e.j.hoorn@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>ErasmusMC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan L van Saase, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 29, 2015</lastchanged_date>
  <firstreceived_date>December 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Ewout Hoorn</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sodium Chloride Symporter Inhibitors</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
